Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation.
-
GSK delivers Q3 sales of £8.1 billion, +3% AER, +6% CER
Total EPS 28.8p, +16% AER, +23% CER; Adjusted EPS 35.5p, +10% AER, + 14% CER
-
GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Marked patient benefit observed in phase II study supports further clinical development of GSK3196165 for RA.
-
ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV
Priority review voucher used with NDA submission with anticipated target action date of six months.
-
Positive results from Harmony Outcomes study of albiglutide published in The Lancet (1)
GSK and the Duke Clinical Research Institute (DCRI) today announced publication of positive results from the Harmony Outcomes study.
-
GSK ships 2018-19 seasonal influenza vaccines for US market
GSK will begin shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2018-19 flu season.
-
GSK Science in the Summer classes kick-off across the nation
GSK Science in the Summer launches the Science of Space for elementary school students in 2nd through 6th grades.
-
GSK presents college scholarships to Philadelphia students who have overcome adversity to pursue their dreams
Media representatives are invited to GSK to attend a special event honoring the 2018 winners of the GSK Opportunity Scholarship program.
-
GSK presents college scholarships to Triangle Region, NC students who have overcome adversity to pursue their dreams
Media representatives are invited to GSK to attend a special event honoring the 2018 winners of the GSK Opportunity Scholarship program.
-
Local nonprofits make a bigger IMPACT with $40,000 award from GSK in the Triangle region of North Carolina
GSK and Triangle Community Foundation today issued the call for applications for the 2018 GSK IMPACT Awards.
-
Local nonprofits make a bigger IMPACT with $40,000 award from GSK in Greater Philadelphia region
GSK and The Philadelphia Foundation today issued the call for applications for the 2018 GSK IMPACT Awards.
-
Summer Will Be Out of This World for Elementary School Students with GSK Science in the Summer™ and the Science of Space
Free STEM program returns to libraries and community centers across the country
-
Sensodyne® Rapid Relief Launches in the United States
New toothpaste provides clinically-proven relief from tooth sensitivity in just three days
-
GSK presents new efficacy data for FLUARIX® QUADRIVALENT (Influenza Vaccine) in children 6 months through 35 months of age
GSK presented today at the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices
-
Summer Will Be Out of This World for Philly-Area Students with GSK Science in the Summer™ & the Science of Space
Free STEM program returns to local libraries this summer for the 32nd year. Online registration begins in May 2018.
-
GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older
GSK announced today it has received approval from the US FDA) expanding the indication for FLUARIX® QUADRIVALENT
-
GSK honors Triangle nonprofits making a positive IMPACT on health outcomes
Ten Triangle, NC nonprofits will receive $40,000 a GSK IMPACT Award
-
GSK honors Triangle nonprofits making a positive IMPACT on health outcomes in NC
GSK and Triangle Community Foundation honor ten local nonprofit organizations with $40,000 GSK IMPACT Awards
-
GSK IMPACT Awards for Greater Philadelphia
GSK honors Philadelphia-area nonprofits making a positive IMPACT on health outcomes.
-
GSK presents new data at ACR for BENLYSTA (belimumab) for subcutaneous use (SC) showing improvement in multiple organ domains
GSK today announced results from BLISS-SC, a 52-week study for Benlysta(belimumab) subcutaneous (SC)
